NASDAQ · ALMSHealthcarePharmaceuticals

Alumis financials

$7.29+1.82%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
Revenue$24.1M$0.00
Gross profit$24.1M$0.00
Gross margin100.0%—
Operating income-$453.8M-$300.8M
Net income-$243.3M-$294.2M
Net margin−1011.7%—
Diluted EPS$-2.86$-10.38
EBITDA-$450.3M-$297.6M
Operating cash flow-$369.5M-$255.1M
Free cash flow-$370.2M-$256.8M
Diluted shares85.0M28.3M

Balance sheet

Period endDec 31Dec 31
Cash & equivalents$89.7M$169.5M
Short-term investments$218.8M$118.7M
Total debt$0.00$0.00
Total assets$411.9M$341.0M
Total liabilities$110.6M$80.9M
Shareholders' equity$301.3M$260.1M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology